WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, May 23, 2007, 27(21):5615-5620; doi:10.1523/JNEUROSCI.0027-07.2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in J. Neurosci.
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Solinas, M.
Right arrow Articles by Goldberg, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Solinas, M.
Right arrow Articles by Goldberg, S. R.

 Previous Article  |  Next Article 

Brief Communications
Nicotinic {alpha}7 Receptors as a New Target for Treatment of Cannabis Abuse

Marcello Solinas,1,2 Maria Scherma,2,4 Liana Fattore,5 Jessica Stroik,2 Carrie Wertheim,2 Gianluigi Tanda,3 Walter Fratta,4 and Steven R. Goldberg2

1Institut de Biologie et Physiologie Cellulaires, Centre National de la Recherche Scientifique-6187, University of Poitiers, 86022 Poitiers, France, 2Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, and 3Psychobiology Section, Medications Discovery Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland 21224, 4B. B. Brodie Department of Neuroscience, University of Cagliari, 09024 Cagliari, Italy, and 5Institute of Neuroscience, National Research Council, Consiglio Nazionale delle Ricerche Italy, 09024 Cagliari, Italy

Correspondence should be addressed to Steven R. Goldberg, Preclinical Pharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, 5500 Nathan Shock Drive, Baltimore, MD 21224. Email: sgoldber{at}intra.nida.nih.gov

Increasing use of cannabis makes the search for medications to reduce cannabis abuse extremely important. Here, we show that homomeric {alpha}7 nicotinic receptors are novel molecular entities that could be targeted in the development of new drugs for the treatment of cannabis dependence. In rats, systemic administration of the selective {alpha}7 nicotinic acetylcholine receptor antagonist methyllycaconitine (MLA), but not the selective heteromeric non-{alpha}7 nicotinic acetylcholine receptor antagonist dihydrobetaerythroidine, (1) antagonized the discriminative effects of {delta}-9-tetrahydrocannabinol (THC), the main active ingredient in cannabis, (2) reduced intravenous self-administration of the synthetic cannabinoid CB1 receptor agonist WIN55,212-2 [(R)-(+)-[2,3-dihydro-5-methyl-3[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone, mesylate salt], and (3) decreased THC-induced dopamine elevations in the shell of the nucleus accumbens. Altogether, our results indicate that blockade of {alpha}7 nicotinic receptors reverses abuse-related behavioral and neurochemical effects of cannabinoids. Importantly, MLA reversed the effects of cannabinoids at doses that did not produce depressant or toxic effects, further pointing to {alpha}7 nicotinic antagonists as potentially useful agents in the treatment of cannabis abuse in humans.

Key words: abuse; acetylcholine receptor; cannabinoids; dopamine; behavior; nucleus accumbens


Received Jan. 4, 2007; revised March 28, 2007; accepted April 17, 2007.

Correspondence should be addressed to Steven R. Goldberg, Preclinical Pharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, 5500 Nathan Shock Drive, Baltimore, MD 21224. Email: sgoldber{at}intra.nida.nih.gov


Related articles in J. Neurosci.:

This Week in The Journal

J. Neurosci. 2007 27: i. [Full Text]  



This article has been cited by other articles:


Home page
Physiol. Rev.Home page
E. X. Albuquerque, E. F. R. Pereira, M. Alkondon, and S. W. Rogers
Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function
Physiol Rev, January 1, 2009; 89(1): 73 - 120.
[Abstract] [Full Text] [PDF]



-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-